Connect with us

News

Record numbers of women are freezing their eggs, data shows

Egg and embryo freezing cycles are the fastest growing treatments in the UK

Published

on

More people than ever before are having fertility treatment as new data shows a 64 per cent increase in egg freezing and fertility preservation cycles.

The Fertility Treatment 2021: Preliminary Trends and Figures report, published by the Human Fertilisation & Embryology Authority (HFEA), has shown that around 55,000 patients had IVF or donor insemination treatment at UK licensed fertility clinics in 2021, compared to 53,000 in 2019.

The data has found that 83,000 IVF and donor insemination cycles were carried out in 2021 compared to 76,000 in 2019.

It has also revealed record numbers of patients are freezing their eggs for future use with 4,000 in 2021 compared to around 2,500 in 2019 (a 64 per cent rise).

The report, which shows how many patients undergo fertility treatment each year in UK fertility clinics, the type of treatment they have and the success rate, also shows the average pregnancy rate from IVF.

It suggests pregnancy rates using fresh embryo transfers have increased, rising to 29 per cent per embryo transferred in 2021 from 10 per cent in 1991.

“Overall, the new HFEA report paints a promising picture,” says Julia Chain, chair of the Human Fertilisation & Embryology Authority (HFEA).

“It shows treatment numbers are back at pre pandemic levels and thanks to improved clinical and laboratory practice, over time pregnancy rates are increasing.

“Despite the pandemic being declared officially over, the aftershocks are still being felt as delays across other areas of healthcare prevent some patients accessing fertility services.

“Our report shows that the average age of IVF patients has increased to 36, around five years older than mothers who get pregnant naturally and these aftershocks could mean that the average age of an IVF patient continues to rise.

“Although pregnancy rates have increased, the likelihood of success decreases with age. For some patients, this may mean they never get the baby they hoped for and that’s heart breaking.”

The Fertility Treatment 2021: Preliminary Trends and Figures report also shows:

  • IVF cycles increased to 76,000 cycles in 2021 from almost 70,000 in 2019
  • There were 11 times more egg freeze cycles in 2021 than in 2011; 373 cycles in 2011 compared to 4,215 cycles in 2021. The number of embryo freeze cycles increased from 230 cycles in 2011 to 10,719 in 2021.
  • In 2021, the average IVF pregnancy rate using fresh embryo transfers for patients aged 18-34 was 41 per cent per embryo transferred with a birth rate of 33 per cent. This compares to six per cent for patients aged 43-50 when using their own eggs and a birth rate of four per cent.
  • Single patients and patients in female same-sex relationships had the largest increase in IVF usage from 2019 to 2021.
  • The use of private funding by patients across the UK aged 18-34 has continued to increase with 63 per cent of IVF cycles funded privately in 2021 compared to 52 per cent in 2019.
  • The number of IVF cycles funded by the NHS continued to vary across the UK with an overall decrease to 20,000 cycles in 2021 from around 24,000 in 2019 (-16 per cent).

The fertility sector is a unique area of healthcare in the UK as the majority of patients pay for treatment themselves.

The proportion of NHS funded cycles have decreased right across the UK between 2019 and 2021, with data showing a 17 per cent reduction of NHS funded IVF cycles in England, 36 per cent in Wales and one per cent in Scotland.

“There were just under 4,000 fewer IVF cycles funded through the NHS between 2019 and 2021 so although more people than ever are having fertility treatment, our data shows that more people than ever are now also paying for it,” explains Chain.

“There could be several reasons why NHS funded cycles lag behind those seen before the pandemic.

“Firstly, we’ve seen a change in the type of family accessing fertility treatment with clinics treating 44 per cent more single patients and 33 per cent more patients in same sex female couples in 2021 than they did in 2019.

“Secondly, funding criteria varies depending on where you live and under current rules, very few single and same sex patients qualify for NHS funding,” she continues.

“And finally, measures put in place during the Covid-19 pandemic saw clinics prioritise older patients and this combined with waiting list backlogs elsewhere in the NHS, could mean that women are no longer eligible for NHS funding by the time they are referred for fertility treatment.”

Diagnosis

Lung cancer drug shows breast cancer potential

Published

on

Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.

PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.

Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.

The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.

In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.

Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.

Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.

Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”

John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”

Continue Reading

Insight

Higher nighttime temps linked to increased risk of autism diagnosis in children – study

Published

on

Nighttime temperatures during pregnancy may be linked to a higher chance of an autism diagnosis in children, a recent study suggests.

The research tracked nearly 295,000 mother-child pairs in Southern California from 2001 to 2014 and linked warmer overnight temperatures with higher risk in early and late pregnancy.

Children of mothers exposed to higher than typical nighttime temperatures during weeks one to 10 of pregnancy had a 15 per cent higher risk of an autism diagnosis.

Exposure during weeks 30 to 37 was linked to a 13 per cent higher risk.

 Lead author David Luglio, a post-doctoral fellow at Tulane University, said: “A key takeaway is that we identified specific windows when a mother and her developing child can be most affected by exposures to higher nighttime temperatures.

“This is critical and hopefully can help mothers prepare accordingly.”

The study is described as the first to examine how temperature may affect fetal neurodevelopment, the process by which a baby’s brain and nervous system form during pregnancy.

Extreme temperatures linked to increased risk were classified as above the 90th percentile, meaning 3.6°F hotter than average, and the 99th percentile, 5.6°F above average.

The association held even after researchers accounted for factors such as neighbourhood conditions, vegetation and fine-particle air pollution.

The study could not account for other factors such as access to air conditioning. Researchers did not find the same association with daytime temperatures, potentially because people spend more time away from home during the day.

“Heat waves are becoming more frequent, and people may only think of the dangers of daytime heat exposure,” said Mostafijur Rahman, assistant professor of environmental health sciences at Tulane University.

“These results indicate a strong association between high nighttime temperatures during pregnancy and autism risk in children and show that we need to think about exposure to heat around the clock.”

The study did not examine how higher temperatures at night might affect prenatal development, though Luglio said it is possible that warmer nights disrupt sleep for pregnant mothers.

Previous research has suggested insufficient sleep during pregnancy may be linked to a higher risk of neurocognitive delays in children.

“Extreme heat exposure during pregnancy has been linked to a range of adverse health outcomes, including prenatal neurodevelopment delays and complications with an embryo’s development of a central nervous system,” Luglio said.

“The goal of our study was to specifically explore the link between prenatal heat exposure and autism diagnoses for the first time.”

Continue Reading

Entrepreneur

Kindbody unveils next-gen fertility platform

Published

on

Kindbody has launched a fertility platform integrating AI with clinical care and patient support for employers and health plans.

The platform will enter a pilot with select Kindbody employer clients in 2026, covering over three million lives, ahead of wider availability in 2027.

Building on the company’s clinical model, the platform aims to improve outcomes and cost efficiency across family-building journeys. It connects Kindbody-owned clinics, partner clinics and an integrated clinical app.

The app offers virtual care across conception, pregnancy and reproductive health, extending through the menopause transition.

Launch features include updates in medication management, third-party reproduction, adoption, pregnancy, men’s health and global programme design.

David Stern, chief executive of Kindbody, said: “With our next-generation fertility platform, Kindbody is redefining what comprehensive, intelligent and affordable family-building care looks like for employers, health plans and patients.

“By unifying best-in-class clinical care, AI-driven intelligence and whole-person support, we are making it easier and more cost-effective for more people to build the families they envision.”

Kindbody has expanded access via its national network of IVF centres, including IVIRMA, Inception Fertility and Ivy Fertility.

A new Fertility Medication Portal is designed to streamline authorisations so medicines can be dispensed on time, giving patients visibility from prescription to coverage, pharmacy fulfilment and delivery tracking.

Through KindMan, men’s health education, digital resources and integrated clinical care are expanding, including hormone management programmes.

Services cover andropause (age-related testosterone decline), erectile dysfunction, low testosterone and other male reproductive conditions.

Specialist fertility care includes semen analysis, diagnostic testing, male hormone panels, genetic testing, surgical sperm extraction and sperm cryopreservation.

Launching in the second quarter, a pregnancy support app will act as a digital companion for expecting and new parents, with resources, interactive tools and clinical assessments to identify social drivers of health and mental health needs during pregnancy and beyond.

Kindbody’s physician-led menopause programme provides consultations with board-certified obstetricians and gynaecologists to diagnose, treat and manage menopausal symptoms, including hormone replacement therapy where appropriate, with support from nutritionists, mental health therapists and pelvic floor specialists.

AI and analytics will be embedded across the care journey. An AI care navigator will guide employees from benefit activation through intake, triage and scheduling.

Tools will track benefits and treatment plans, showing coverage and expected out-of-pocket costs at each step.

AI-supported scribing will assist clinicians with documentation, and a predictor tool will estimate a patient’s likelihood of having a baby across different treatment paths.

In 2027, Kindbody plans a savings model for eligible large employers that it says will guarantee lower total fertility spend while improving clinical efficiency and patient experience.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.